Published in

Elsevier, The Lancet HIV, 8(4), p. e341-e348

DOI: 10.1016/s2352-3018(17)30065-6

Links

Tools

Export citation

Search in Google Scholar

Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial

Journal article published in 2017 by Nicholas I. Paton, Cissy Kityo ORCID, Jennifer Thompson, Immaculate Nankya, Leonard Bagenda, Anne Hoppe, James Hakim, Andrew Kambugu, Joep J. van Oosterhout, Mary Kiconco, Silvia Bertagnolio, Philippa J. Easterbrook, Peter Mugyenyi, A. Sarah Walker, E. Agweng and other authors.
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Green circle
Postprint: archiving allowed
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO